T
Thomas Martin
Researcher at University of California, San Francisco
Publications - 311
Citations - 17918
Thomas Martin is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Medicine & Exocytosis. The author has an hindex of 73, co-authored 242 publications receiving 15771 citations. Previous affiliations of Thomas Martin include Institut national de la recherche agronomique & University of Western Australia.
Papers
More filters
Journal ArticleDOI
B04: combination of subcutaneous teclistamab with daratumumab in patients with relapsed/refractory multiple myeloma (rrmm): results from a phase 1b multicohort study
Paula Rodriguez-Otero,Bhagirathbhai Dholaria,Elham Askari,Donna E. Reece,N. W. van de Donk,Ajai Chari,Hartmut Goldschmidt,Amrita Krishnan,Thomas Martin,M.V. Mateos,Daniel Morillo,Cristian Rodriguez,Laura Rosiñol,J. San Miguel,Anna Sureda Balari,Ralph Wäsch,Katja Weisel,Rodrido Luiz Costa Verona,Timothy Prior,Margaret Gaston Wade,Brendan M. Weiss,John M. Goldberg,Albert Oriol,Parameswaran Hari +23 more
Journal ArticleDOI
Recent Advances in the Use of Chimeric Antigen Receptor-Expressing T-Cell Therapies for Treatment of Multiple Myeloma.
TL;DR: In this article , the authors provide an overview of recently updated clinical trial data and indirect treatment comparison analyses regarding two clinically advanced CAR-T therapies, idecabtagene vicleucel (ide-cel) and ciltacabagtagene autoleucel(cilta-cel), for relapsed/refractory multiple myeloma (RRMM).
Journal ArticleDOI
Effects of TRH on Secondary Messenger Systems: Summary of Section IV
TL;DR: This section focused on postreceptor actions of TRH in the pituitary gland including its receptor-associated transduction mechanism involving phosphoinositide turnover and its effects on posttranslational processing of TSH.
Journal ArticleDOI
MM-086 Real-World Experience With Isatuximab (Isa) in Patients With Relapsed and/or Refractory Multiple Myeloma: IONA-MM First Interim Analysis.
Elisabet E. Manasanch,Meral Beksac,Michele Cavo,Wolfgang Knauf,Nobuhiro Tsukada,Christina Tekle,Zhen-huan Zhao,Thomas Martin +7 more
TL;DR: IONA-MM as discussed by the authors is a non-interventional study, where patients with relapsed and/or refractory multiple myeloma (RRMM) were enrolled prospectively/retrospectively (Isaexposed ≤3 months pre-enrollment).
Journal ArticleDOI
Outcomes of Plasma Cell Leukemia Patients in the Era of Next-Generation Novel Agents: A Single-Center Retrospective Cohort Study
TL;DR: A single-center, retrospective study of patients who at diagnosis had pPCL or had MM with < 20% CPCs, finding that next-generation agents such as carfilzomib (CFZ), pomalidomide, and daratumumab (DARA) are still scarce.